Thrombotic thrombocytopenic purpura epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
 
(10 intermediate revisions by the same user not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Xyz}}
{{Thrombotic thrombocytopenic purpura}}


{{CMG}}; {{AE}}  
{{CMG}}; {{AE}} {{S.G.}}
==Overview==
==Overview==
The most proportion of TTP cases occurred after 40 years, black race and femal sex. Congenital forms  occur in children.


==Epidemiology and Demographics==
==Epidemiology and Demographics==
===Incidence===
===Incidence===
*The incidence of acuired TTP is about 0.3 per 100,000 adult per year <ref name=":0" />.
*The incidence of acuired TTP is about 0.3 per 100,000 adult per year.<ref name="pmid237293722">{{cite journal |vauthors=Reese JA, Muthurajah DS, Kremer Hovinga JA, Vesely SK, Terrell DR, George JN |title=Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features |journal=Pediatr Blood Cancer |volume=60 |issue=10 |pages=1676–82 |date=October 2013 |pmid=23729372 |doi=10.1002/pbc.24612 |url=}}</ref>
* Data suggests the increased risk of TTP in black race and femal sex <ref name="pmid20799358" />.
* Data suggests the increased risk of TTP in black race and femal sex.<ref name="pmid207993582">{{cite journal |vauthors=Terrell DR, Vesely SK, Kremer Hovinga JA, Lämmle B, George JN |title=Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromes |journal=Am. J. Hematol. |volume=85 |issue=11 |pages=844–7 |date=November 2010 |pmid=20799358 |pmc=3420337 |doi=10.1002/ajh.21833 |url=}}</ref>


===Prevalence===
===Prevalence===
*The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
*The incidence of TTP is approximately [number range] per 100,000 individuals worldwide.<ref name="pmid159781002">{{cite journal |vauthors=Terrell DR, Williams LA, Vesely SK, Lämmle B, Hovinga JA, George JN |title=The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency |journal=J. Thromb. Haemost. |volume=3 |issue=7 |pages=1432–6 |date=July 2005 |pmid=15978100 |doi=10.1111/j.1538-7836.2005.01436.x |url=}}</ref>
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
*In 2005, the prevalence of TTP was estimated to be 3 cases per 1000,000 individuals worldwide.<ref name="pmid15978100">{{cite journal |vauthors=Terrell DR, Williams LA, Vesely SK, Lämmle B, Hovinga JA, George JN |title=The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency |journal=J. Thromb. Haemost. |volume=3 |issue=7 |pages=1432–6 |date=July 2005 |pmid=15978100 |doi=10.1111/j.1538-7836.2005.01436.x |url=}}</ref>
*The prevalence of [disease/malignancy] is estimated to be [number] cases annually.
 
===Case-fatality rate/Mortality rate===
*In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
*The case-fatality rate/mortality rate of [disease name] is approximately [number range].


===Age===
===Age===
*Patients of all age groups may develop [disease name].
*Patients of all age groups may developTTP.  
*The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
*The incidence of TTP increases with age; the median age at diagnosis is 40 years. TTP often occurs after 40 years.
*[Disease name] commonly affects individuals younger than/older than [number of years] years of age.
*[Chronic disease name] is usually first diagnosed among [age group].
*[Acute disease name] commonly affects [age group].


===Race===
===Race===
*There is no racial predilection to [disease name].
*TTP usually affects individuals of the black [[race]].<ref name="pmid20799358">{{cite journal |vauthors=Terrell DR, Vesely SK, Kremer Hovinga JA, Lämmle B, George JN |title=Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromes |journal=Am. J. Hematol. |volume=85 |issue=11 |pages=844–7 |date=November 2010 |pmid=20799358 |pmc=3420337 |doi=10.1002/ajh.21833 |url=}}</ref><ref name="pmid273832022">{{cite journal |vauthors=Martino S, Jamme M, Deligny C, Busson M, Loiseau P, Azoulay E, Galicier L, Pène F, Provôt F, Dossier A, Saheb S, Veyradier A, Coppo P |title=Thrombotic Thrombocytopenic Purpura in Black People: Impact of Ethnicity on Survival and Genetic Risk Factors |journal=PLoS ONE |volume=11 |issue=7 |pages=e0156679 |date=2016 |pmid=27383202 |pmc=4934773 |doi=10.1371/journal.pone.0156679 |url=}}</ref>
*[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
===Gender===
===Gender===
*[Disease name] affects men and women equally.
*Females are more commonly affected by TTP than men. The females to men ratio is approximately 2 to 1.<ref name="pmid20799358" /><ref name="pmid23729372">{{cite journal |vauthors=Reese JA, Muthurajah DS, Kremer Hovinga JA, Vesely SK, Terrell DR, George JN |title=Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features |journal=Pediatr Blood Cancer |volume=60 |issue=10 |pages=1676–82 |date=October 2013 |pmid=23729372 |doi=10.1002/pbc.24612 |url=}}</ref>
*[Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.


===Region===
===Region===
*The majority of [disease name] cases are reported in [geographical region].
*The majority of TTP cases are reported in black african and caribbean people.<ref name="pmid27383202">{{cite journal |vauthors=Martino S, Jamme M, Deligny C, Busson M, Loiseau P, Azoulay E, Galicier L, Pène F, Provôt F, Dossier A, Saheb S, Veyradier A, Coppo P |title=Thrombotic Thrombocytopenic Purpura in Black People: Impact of Ethnicity on Survival and Genetic Risk Factors |journal=PLoS ONE |volume=11 |issue=7 |pages=e0156679 |date=2016 |pmid=27383202 |pmc=4934773 |doi=10.1371/journal.pone.0156679 |url=}}</ref>


*[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
===Developed Countries===
===Developing Countries===


==References==
==References==
Line 50: Line 36:




Please help WikiDoc by adding more content here.  It's easy!  Click  [[Help:How_to_Edit_a_Page|here]]  to learn about editing.  
Please help WikiDoc by adding more content here.  It's easy!  Click  [[Help:How_to_Edit_a_Page|here]]  to learn about editing.
 
{{Thrombotic thrombocytopenic purpura}}
{{CMG}} {{AE}} {{Saeedeh}}
==Overview==
==References==
{{reflist|2}}
{{WH}}
{{WS}}
[[Category:Disease]]
[[Category:Autoimmune diseases]]
[[Category:Hematology]]
[[Category:Rare diseases]]
[[Category:Dermatology]]
[[Category:Needs content]]

Latest revision as of 17:11, 3 October 2018

Thrombotic thrombocytopenic purpura Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Thrombotic thrombocytopenic purpura from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Peripheral Smear

Direct Coombs Test

von Willebrand Factor-cleaving Protease Activity

X-ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Thrombotic thrombocytopenic purpura epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Thrombotic thrombocytopenic purpura epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Thrombotic thrombocytopenic purpura epidemiology and demographics

CDC on Thrombotic thrombocytopenic purpura epidemiology and demographics

Thrombotic thrombocytopenic purpura epidemiology and demographics in the news

Blogs on Thrombotic thrombocytopenic purpura epidemiology and demographics

Directions to Hospitals Treating Thrombotic thrombocytopenic purpura

Risk calculators and risk factors for Thrombotic thrombocytopenic purpura epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]

Overview

The most proportion of TTP cases occurred after 40 years, black race and femal sex. Congenital forms occur in children.

Epidemiology and Demographics

Incidence

  • The incidence of acuired TTP is about 0.3 per 100,000 adult per year.[1]
  • Data suggests the increased risk of TTP in black race and femal sex.[2]

Prevalence

  • The incidence of TTP is approximately [number range] per 100,000 individuals worldwide.[3]
  • In 2005, the prevalence of TTP was estimated to be 3 cases per 1000,000 individuals worldwide.[4]

Age

  • Patients of all age groups may developTTP.
  • The incidence of TTP increases with age; the median age at diagnosis is 40 years. TTP often occurs after 40 years.

Race

  • TTP usually affects individuals of the black race.[5][6]

Gender

  • Females are more commonly affected by TTP than men. The females to men ratio is approximately 2 to 1.[5][7]

Region

  • The majority of TTP cases are reported in black african and caribbean people.[8]


References

  1. ↑ Reese JA, Muthurajah DS, Kremer Hovinga JA, Vesely SK, Terrell DR, George JN (October 2013). "Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features". Pediatr Blood Cancer. 60 (10): 1676–82. doi:10.1002/pbc.24612. PMID 23729372.
  2. ↑ Terrell DR, Vesely SK, Kremer Hovinga JA, Lämmle B, George JN (November 2010). "Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromes". Am. J. Hematol. 85 (11): 844–7. doi:10.1002/ajh.21833. PMC 3420337. PMID 20799358.
  3. ↑ Terrell DR, Williams LA, Vesely SK, Lämmle B, Hovinga JA, George JN (July 2005). "The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency". J. Thromb. Haemost. 3 (7): 1432–6. doi:10.1111/j.1538-7836.2005.01436.x. PMID 15978100.
  4. ↑ Terrell DR, Williams LA, Vesely SK, Lämmle B, Hovinga JA, George JN (July 2005). "The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency". J. Thromb. Haemost. 3 (7): 1432–6. doi:10.1111/j.1538-7836.2005.01436.x. PMID 15978100.
  5. ↑ 5.0 5.1 Terrell DR, Vesely SK, Kremer Hovinga JA, Lämmle B, George JN (November 2010). "Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromes". Am. J. Hematol. 85 (11): 844–7. doi:10.1002/ajh.21833. PMC 3420337. PMID 20799358.
  6. ↑ Martino S, Jamme M, Deligny C, Busson M, Loiseau P, Azoulay E, Galicier L, Pène F, Provôt F, Dossier A, Saheb S, Veyradier A, Coppo P (2016). "Thrombotic Thrombocytopenic Purpura in Black People: Impact of Ethnicity on Survival and Genetic Risk Factors". PLoS ONE. 11 (7): e0156679. doi:10.1371/journal.pone.0156679. PMC 4934773. PMID 27383202.
  7. ↑ Reese JA, Muthurajah DS, Kremer Hovinga JA, Vesely SK, Terrell DR, George JN (October 2013). "Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features". Pediatr Blood Cancer. 60 (10): 1676–82. doi:10.1002/pbc.24612. PMID 23729372.
  8. ↑ Martino S, Jamme M, Deligny C, Busson M, Loiseau P, Azoulay E, Galicier L, Pène F, Provôt F, Dossier A, Saheb S, Veyradier A, Coppo P (2016). "Thrombotic Thrombocytopenic Purpura in Black People: Impact of Ethnicity on Survival and Genetic Risk Factors". PLoS ONE. 11 (7): e0156679. doi:10.1371/journal.pone.0156679. PMC 4934773. PMID 27383202.

Template:WH Template:WS


Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Retrieved from "https://www.wikidoc.org/index.php?title=Thrombotic_thrombocytopenic_purpura_epidemiology_and_demographics&oldid=1496362"